Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Endymion in Advanced Parkinson's Disease
jRCTs041260100Phase 2Not yet recruiting
- Sponsor
- Learning Health Systems Institute
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melatonin in Parkinson's disease (PD), sponsored by Learning Health Systems Institute. Primary endpoint: Adverse Event. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
melatonin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCTs041260100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260100.